Nurix Therapeutics Stock Probability of Future Stock Price Finishing Over 33.41
| NRIX Stock | USD 19.11 0.82 4.11% |
Nurix |
Nurix Therapeutics Target Price Odds to finish over 33.41
The tendency of Nurix Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 33.41 or more in 90 days |
| 19.11 | 90 days | 33.41 | near 1 |
Based on a normal probability distribution, the odds of Nurix Therapeutics to move over $ 33.41 or more in 90 days from now is near 1 (This Nurix Therapeutics probability density function shows the probability of Nurix Stock to fall within a particular range of prices over 90 days) . Probability of Nurix Therapeutics price to stay between its current price of $ 19.11 and $ 33.41 at the end of the 90-day period is over 95.36 .
Given the investment horizon of 90 days Nurix Therapeutics has a beta of 0.14. This indicates as returns on the market go up, Nurix Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Nurix Therapeutics will be expected to be much smaller as well. Additionally Nurix Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Nurix Therapeutics Price Density |
| Price |
Predictive Modules for Nurix Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Nurix Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Nurix Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Nurix Therapeutics is not an exception. The market had few large corrections towards the Nurix Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Nurix Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Nurix Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.26 | |
β | Beta against Dow Jones | 0.14 | |
σ | Overall volatility | 2.35 | |
Ir | Information ratio | -0.08 |
Nurix Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Nurix Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Nurix Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Nurix Therapeutics generated a negative expected return over the last 90 days | |
| Nurix Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 76.99 M. Net Loss for the year was (143.95 M) with loss before overhead, payroll, taxes, and interest of (145.87 M). | |
| Nurix Therapeutics currently holds about 344.48 M in cash with (81.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstroms Macroglobulinemia |
Nurix Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Nurix Stock often depends not only on the future outlook of the current and potential Nurix Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Nurix Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 54.3 M | |
| Cash And Short Term Investments | 287.9 M |
Nurix Therapeutics Technical Analysis
Nurix Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Nurix Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Nurix Therapeutics. In general, you should focus on analyzing Nurix Stock price patterns and their correlations with different microeconomic environments and drivers.
Nurix Therapeutics Predictive Forecast Models
Nurix Therapeutics' time-series forecasting models is one of many Nurix Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Nurix Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Nurix Therapeutics
Checking the ongoing alerts about Nurix Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Nurix Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Nurix Therapeutics generated a negative expected return over the last 90 days | |
| Nurix Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 76.99 M. Net Loss for the year was (143.95 M) with loss before overhead, payroll, taxes, and interest of (145.87 M). | |
| Nurix Therapeutics currently holds about 344.48 M in cash with (81.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstroms Macroglobulinemia |
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.